Predicting response to CGRP-monoclonal antibodies in patients with migraine in Japan: a single-centre retrospective observational studyKeiko Ihara, Tsubasa Takizawa, Seiya Ohtani et al.|The Journal of Headache and Pain|2023Cited by 82
Real-world evidence of galcanezumab for migraine treatment in Japan: a retrospective analysisTsubasa Takizawa, Jin Nakahara, Seiya Ohtani et al.|BMC Neurology|2022Cited by 67
Switching between anti-calcitonin gene-related peptide monoclonal antibodies: A comparison of monthly and quarterly dosingKeiko Ihara, Tsubasa Takizawa, Jin Nakahara et al.|Journal of the Neurological Sciences|2023Cited by 23
Dysautonomia associated with immune checkpoint inhibitorsToshiki Tezuka, Shigeaki Suzuki, Shinichi Okuzumi et al.|Journal of Neurology|2023Cited by 20
Real-world evidence of fremanezumab for treating migraine in Japan: a retrospective studySeiya Ohtani, Tsubasa Takizawa, Narumi Watanabe et al.|BMC Neurology|2023Cited by 15